Project Grant R43GM159507
Award Date 9/15/25
Completion Date 9/14/26
Dollars Obligated $357K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Alachua, FL 32615, USA
Similar Awards
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
- This SBIR Phase I Project Grant award of $298,646, provided by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a rapid diagnostic test for identifying sepsis-causing pathogens from small blood volumes. The proposed DNA-based technology seeks to comprehensively detect and quantify a wide range of pathogens within a few hours, addressing limitations of current culture-based methods that require larger blood samples and...
- The National Institute of General Medical Sciences (NIGMS) awarded a $350,000 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Medosome Biotec LLC, a for-profit limited liability company. The grant, awarded on September 12, 2024, will support research and development to evaluate the safety and therapeutic potential of dichloroacetate (DCA) as a treatment for sepsis. Medosome Biotec will collaborate with researchers at the University of Florida, Wake...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $473,937 Project Grant to The General Hospital Corporation (d/b/a Massachusetts General Hospital) for the project "Novel Point-of-Care Liquid Biopsy for Early Detection of Sepsis-Associated Organ Damage". The project aims to develop a novel circulating cellular biomarker for the early detection and assessment of...
- The U.S. Centers for Disease Control and Prevention (CDC) awarded a $501,200 Project Grant on Sep 30, 2025 to Aptus Biosciences LLC, a minority-owned small business located in Gainesville, Florida, under the CDC's "Prevention of Disease, Disability, and Death by Infectious Diseases" program (CFDA 93.084). The funding will support the development of a rapid, affordable, aptamer-based diagnostic test for Hepatitis C virus. Aptus Biosciences specializes in advanced diagnostic research and...
- This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), will develop living biosensors to detect and analyze DNA at the single-base level without requiring sample purification or specialized equipment. The $565,614 award will produce a hybrid living biosensor/lateral flow assay that can rapidly detect target DNA sequences,...
- This $305,000 project grant awarded by the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of a clinical decision support system (CDSS) called Sepsis FLO. The CDSS is designed to precisely guide blood volume diagnosis and treatment for sepsis patients. Key activities include: 1) Developing an alpha prototype of the CDSS through user-centered design; 2) Validating three functional...
- The National Institute of General Medical Sciences (NIGMS) awarded Attogene Corporation, a biotechnology company based in Austin, Texas, a $229,975 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to develop a rapid, portable, and sensitive test for detecting ribonucleases (RNases). The grant supports the company's efforts to create a novel lateral flow assay prototype that can quickly identify RNase contamination, which is critical for ensuring quality...
- This $306,782 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the continued development and validation of a panel of six sialoglycan-recognizing probes (SGRPs) by Z Biotech, LLC. The project aims to optimize these specialized molecular tools, which leverage naturally evolved microbial sialoglycan-binding proteins, for use in common laboratory techniques like ELISA, Western...
- The U.S. National Institute of General Medical Sciences (NIGMS), through the Biomedical Research and Research Training federal grant program (CFDA 93.859), awarded a $432,834 Project Grant to the Board of Regents of the University of Nebraska on April 15, 2025. The grant supports the development of an "enzyme-free, label-free quantitative microarray technology" to detect and quantify target nucleic acids, such as microRNA, with high sensitivity down to the attomolar (10^-18 M) range....